Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001047166 | SCV001211103 | uncertain significance | PTEN hamartoma tumor syndrome | 2024-07-23 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 165 of the PTEN protein (p.Gly165Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Cowden syndrome (PMID: 10234502). ClinVar contains an entry for this variant (Variation ID: 844343). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects PTEN function (PMID: 21828076). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Victorian Clinical Genetics Services, |
RCV002471014 | SCV002766831 | pathogenic | Cowden syndrome 1 | 2022-03-31 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative and loss of function are known mechanisms of disease in this gene and are associated with hamartoma tumour syndrome. Loss of function is the mechanism for null variants while missense variants have been proven to exert either a loss of function or dominant-negative mechanism (GeneReviews). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. In particular, PTEN-related Proteus syndrome has been described to be a highly variable disorder (GeneReviews). (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to glutamic acid. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. While the variant lies within a splice region and the nucleotide is highly conserved, in silico tools do not predict abberant splicing. (SP) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0703 - Other missense variants comparable to the one identified in this case have moderate previous evidence for pathogenicity. p.(Gly165Arg) has been classified as pathogenic by an expert panel in ClinVar and identified in at least two individuals from a Cowden/Cowden-like/ Bannayan-Riley-Ruvalcaba syndrome cohort and de novo in one individual with macrocephaly, who also had a dual diagnosis of KMT2E-related disorder (PMID: 21659347, 25669429, 31079897). In addition, p.(Gly165Val) has been identified in one individual with Cowden syndrome and three other individuals whose clinical phenotypes were not provided (PMID: 9467011, 31594918). (SP) 0803 - This variant has limited previous evidence of pathogenicity in an unrelated individual. It has been identified in one individual with Cowden syndrome (PMID: 10234502). It was noted however, the variant has been classified as a VUS by a diagnostic laboratory in ClinVar. (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. In vitro assays demonstrated markedly reduced protein activity (PMID: 21828076). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |